The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
The determinants of tumour immunogenicity
Open accessAbstract
Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Cells and macromolecules cannot easily penetrate into the tumour microenvironment owing to physical barriers, such as a dense extracellular matrix (ECM) and a high interstitial fluid pressure that is caused by a lack of lymphatic drainag”
BackgroundTowards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Self-citationHUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Self-citationCancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
CD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · cited 1×
“Consequently, the local tumour immune response becomes increasingly compromised, and the immune cells exhibit reduced effector functions and limited persistence; this limited persistence is emerging as a key factor in the failure of the immune response to control tumour progressio”
BackgroundThe response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
Self-citationCD4 cells can be more efficient at tumor rejection than CD8 cells
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 437
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Gotter, J., Brors, B., Hergenhahn, M., & Kyewski, B. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031677 · Cited by 359
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Self-citationGarrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276
Schumacher, T. N. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri841 · Cited by 274
Controversies in clinical cancer dormancy
Uhr, J. W., & Pantel, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106613108 · Cited by 251
IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS
BURNET, M. (1964) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a070310 · Cited by 239
On immunosurveillance in human cancer.
Thomas, L. (1982) · PubMed Central · Cited by 213
Immunotherapy for pancreatic cancer — science driving clinical progress
Laheru, D., & Jaffee, E. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1630 · Cited by 202
Self-citationChemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
Zheng, L., Foley, K., Huang, L., Leubner, A., Mo, G., Olino, K., Edil, B. H., Mizuma, M., Sharma, R., Le, D. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019390 · Cited by 182
Self-citationDemotte, N., Wieërs, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J.-L., Weynand, B., Carrasco, J., Lurquin, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0761 · Cited by 179
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Self-citationRescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N., & Greenberg, P. D. (2012) · Science · doi:10.1126/science.1214277 · Cited by 169
Klein, G., & Klein, E. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.5.2121 · Cited by 168
Synergy between tumor immunotherapy and antiangiogenic therapy
Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., & Gilboa, E. (2003) · Blood · doi:10.1182/blood-2002-12-3738 · Cited by 163
Self-citationInterdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
Huber, M. L., Haynes, L., Parker, C. C., & Iversen, P. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr514 · Cited by 158
Immune evasion of microsatellite unstable colorectal cancers
Kloor, M., Michel, S., & Doeberitz, M. V. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25283 · Cited by 143
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 136
Self-citationOn the definition of a criterion of immunogenicity
Pradeu, T., & Carosella, E. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608683103 · Cited by 133
Transgenic mice with a diverse human T cell antigen receptor repertoire
Li, L.-P., Lampert, J. C., Chen, X. T., Leitão, C., Popović, J., Müller, W., & Blankenstein, T. J. F. (2010) · Nature Medicine · doi:10.1038/nm.2197 · Cited by 123
Self-citationTumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss, R., & Hanahan, D. (1998) · PubMed · Cited by 121
Willimsky, G., Czéh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., & Blankenstein, T. J. F. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072016 · Cited by 118
Self-citationStrategies to counteract MHC-I defects in tumors
Lampen, M. H., & van Hall, T. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.005 · Cited by 85
Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D. H., & Schendel, D. J. (2009) · Blood · doi:10.1182/blood-2009-03-209387 · Cited by 83
A cancer immunosurveillance controversy
Qin, Z., & Blankenstein, T. J. F. (2003) · Nature Immunology · doi:10.1038/ni0104-3 · Cited by 66
Self-citationCohn, M. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18504.x · Cited by 46
Antigen choice in adoptive T-cell therapy of cancer
Offringa, R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.006 · Cited by 44
Kammertoens, T., Qin, Z., Briesemeister, D., Bendelac, A. S., & Blankenstein, T. J. F. (2011) · International Journal of Cancer · doi:10.1002/ijc.27411 · Cited by 26
Self-citationShankaran, V., Ikeda, H., Bruce, A. T., et al. (2018) · The Journal of Immunology · doi:10.1093/jimmunol/201.3.827 · Cited by 23
Cited by
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330
“CD8 T cells became the central focus of new cancer therapeutics (Blankenstein et al., 2012; Chen and Mellman, 2013; Fridman et al., 2012; Spranger et al., 2013).”
Metadata
- Authors
- Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M.
- Venue
- Nature Reviews Cancer
- Published
- 2012-03-01
- Volume
- 12
- Issue
- 4
- Pages
- 307-313
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2030908446
- Cited by
- 441
- References
- 66
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
